We are live on ! Find out more
OREX

Orexigen Therapeutics, Inc.
OREX

Delisted

OREX was delisted on the 3rd of April, 2018.

Back to rankings

147 hedge funds and large institutions have $654M invested in Orexigen Therapeutics, Inc. in 2014 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 32 increasing their positions, 51 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

117% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 18

52% more capital invested

Capital invested by funds: $431M → $654M (+$223M)

18% more call options, than puts

Call options by funds: $10.2M | Put options by funds: $8.6M

15% more funds holding

Funds holding: 128 → 147 (+19)

37% less repeat investments, than reductions

Existing positions increased: 32 | Existing positions reduced: 51

Holders
147
Holders Change
+19
Holders Change %
+14.84%
% of All Funds
3.92%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.11%
New
39
Increased
32
Reduced
51
Closed
18
Calls
$10.2M
Puts
$8.6M
Net Calls
+$1.57M
Net Calls Change
+$3.57M

Top Buyers

Rank Fund Capital Flow
1
SC
Samlyn Capital
New York
+$17M
2
LCP
Lamond Capital Partners
California
+$9.5M
3
FAM
Fred Alger Management
New York
+$6.54M
4
Morgan Stanley
Morgan Stanley
New York
+$5.29M
5
Millennium Management
Millennium Management
New York
+$4.75M

Top Sellers

Rank Fund Capital Flow
1
Capital Research Global Investors
Capital Research Global Investors
California
-$9.9M
2
RIM
RS Investment Management
California
-$9.5M
3
PHS
PFM Health Sciences
California
-$8.33M
4
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$7.43M
5
FCM
Farallon Capital Management
California
-$3.75M
Name Holding Trade Value Shares
Change 		Change in
Stake
CCA
151
Catalyst Capital Advisors
New York
– -$1.06M -25,000 Closed
JCG
152
JHL Capital Group
Illinois
– -$1.02M -24,000 Closed
VAM
153
Visium Asset Management
New York
– -$534K -12,540 Closed
DY
154
Dowling & Yahnke
California
– -$220K -5,160 Closed
FCE
155
Fiera Capital (Europe)
Cayman Islands
– -$150K -3,520 Closed
NCCM
156
Nine Chapters Capital Management
New Jersey
– -$66K -1,550 Closed
HighTower Advisors
157
HighTower Advisors
Illinois
– -$52K -1,201 Closed
Verition Fund Management
158
Verition Fund Management
Connecticut
– -$43K -1,007 Closed
CCMH
159
Cornerstone Capital Management Holdings
New York
– -$43K -1,005 Closed
EWM
160
Edge Wealth Management
New York
– -$30K -700 Closed
HCM
161
Highlander Capital Management
New Jersey
– -$21.3K -500 Closed
Ameriprise
162
Ameriprise
Minnesota
– -$9K -226 Closed
DADC
163
D.A. Davidson & Co
Montana
– -$8K -200 Closed
TRCT
164
Tower Research Capital (TRC)
New York
– -$1K -30 Closed
3 4 5 6
7

OREX Hedge Fund Activity: Q4 2014 in Review

147 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Orexigen Therapeutics, Inc. (OREX) for Q4 2014, worth a combined $654M — up 52% from $431M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new OREX positions and 18 closed out — a net gain of 21 holders — while 32 added to existing stakes and 51 trimmed.

The largest buyer was Samlyn Capital, adding an estimated $17M. The largest seller was Capital Research Global Investors, cutting an estimated $9.9M.

  • 147 institutional investors held Orexigen Therapeutics, Inc. (OREX) as of Q4 2014, up from 128 in Q3 2014.
  • Funds reported $654M of Orexigen Therapeutics, Inc. stock for Q4 2014, up 52% quarter-over-quarter.
  • 39 funds opened new Orexigen Therapeutics, Inc. positions in Q4 2014 and 18 closed out, a net change of +21 holders.
  • The largest Orexigen Therapeutics, Inc. buyer in Q4 2014 was Samlyn Capital, an estimated $17M added.
  • The largest Orexigen Therapeutics, Inc. seller in Q4 2014 was Capital Research Global Investors, an estimated $9.9M sold.

Based on aggregated 13F filings for Q4 2014.